HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.
about
Pharmacological interventions for treating dyslipidemia in patients with HIV infectionHIV protease inhibitors: a review of molecular selectivity and toxicityRegional gene expression of LOX-1, VCAM-1, and ICAM-1 in aorta of HIV-1 transgenic rats.Inflammation, Immune Activation, and Antiretroviral Therapy in HIVDyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.Prevalence of ischemic heart disease and management of coronary risk in daily clinical practice: results from a Mediterranean cohort of HIV-infected patientsMagnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regionsOngoing impact of HIV infection on mortality among people who inject drugs despite free antiretroviral therapy.Noninvasive coronary imaging for atherosclerosis in human immunodeficiency virus infection.Epidemiology and management of antiretroviral-associated cardiovascular disease.State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors.Switching antiretroviral therapy to minimize metabolic complications.Nutritional status of HIV-positive patients in Niterói, Rio de Janeiro, BrazilRegional fat deposition and cardiovascular risk in HIV infection: the FRAM study.Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South AfricaInflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy.Population-based study of risk factors for coronary heart disease among HIV-infected personsPrevalence of Dyslipidemia Among Antiretroviral-Naive HIV-Infected Individuals in ChinaComplement Component 3 Is Associated with Metabolic Comorbidities in Older HIV-Positive Adults.Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of ageA review of the toxicity of HIV medications.Fenofibrate in the treatment of dyslipidemia associated with HIV infection.Clinical utility of maraviroc.HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults.Ethnic variability in adiposity, thrifty phenotypes and cardiometabolic risk: addressing the full range of ethnicity, including those of mixed ethnicity.An Overview of Human Immunodeficiency Virus Type 1-Associated Common Neurological Complications: Does Aging Pose a Challenge?CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.Lipid Abnormalities and Inflammation in HIV Inflection.Cardiovascular Risk in HIV-Infected and Uninfected Postmenopausal Minority Women: Use of the Framingham Risk Score.Vitamin D Deficiency in HIV-Infected Women on Antiretroviral Therapy Living in the Tropics.Dyslipidaemia and Intima-Media Thickness of Carotid Arteries in Thirty-Five HIV/AIDS Patients Receiving Highly Active Antiretroviral Therapy.Evolution of lipid levels in HIV-infected children treated or not with HAART in Abidjan, Cote d'Ivoire.Adipokines levels in HIV infected patients: lipocalin-2 and fatty acid binding protein-4 as possible markers of HIV and antiretroviral therapy-related adipose tissue inflammation.Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.Development of peptide inhibitors of HIV transmission.Magnitude and associated factors of diabetes mellitus and hypertension among adult HIV-positive individuals receiving highly active antiretroviral therapy at Jugal Hospital, Harar, Ethiopia
P2860
Q24236121-056472D6-4FC3-4539-BFDB-B53585F78AC3Q28082749-D3CE7922-1142-463A-96D7-B55EBF10AA37Q30975430-D02CC609-0A59-4A32-8061-E2462002E67EQ33912595-E7925A83-871A-4BC3-967D-3316BE10AE8FQ33982131-A2B343EF-6627-462B-A36C-A2B439E03E21Q34079798-C9A77CCA-04D6-4413-9F1C-7F925F98CC08Q34168721-2D832452-BC9F-4CEF-84B2-7678B78AD493Q34735099-67156FBE-9995-42DF-9F21-B7ED51A157AAQ35234817-2D21562A-3DC7-437D-912C-6EECCA81B973Q35338096-9121DD0C-78B9-4E08-A75D-7D43AA10E9EBQ35606867-7318A53D-0F9C-4262-9DB6-6E2C64345D9FQ35608074-F9D2DAD8-96A8-45FC-835C-2A26C58BD022Q35627507-98CD9503-93DB-491E-8874-BF80AE4A6665Q35644326-F7905C4B-4E5C-449F-A468-AF85571EE05DQ35856520-C5F9BB57-3C83-4F80-B31E-CFBF87C4229CQ35873877-8EBABD1D-3910-49B3-953E-4DF3BFDAC448Q36291572-4FF58C00-D945-4E91-926A-8B00756BEB5BQ36359159-C14D10CD-70C6-4653-BF87-613D6456C837Q36656773-72C1E7DF-74EF-4693-8AF3-B96DD40E5986Q37080086-765B5231-73A3-4C91-96DA-A4CB50FA0A3DQ37633495-73BF7D20-6C9F-49B6-8356-1AA20BA62B03Q37770249-3092901F-C1C7-4D75-831C-90EC7F74EA6AQ37877242-50CCD6FA-D474-4882-8EE2-F3EA9ED785F0Q38021848-F7C2D3B7-52D6-4966-8AE1-58E49F6C2BBBQ38056227-C0F8C9AA-0E60-4A4E-BBB4-1A86356ABF96Q38628801-1F3D5EEC-BCFA-4B48-9507-F0CD950F8A84Q38803127-A0D63840-983B-4A84-8C27-C8C733EBBEF8Q38849283-C325482A-E17C-4F55-BB18-A7819539C446Q38950123-0C306B6E-EC38-4C8D-AF7F-5811A6EAC4EFQ38951904-FD2488AA-3E0E-4B9B-B3B9-4C83A9C00617Q39529770-3FC63E59-3022-4C5E-AD83-CA430536741BQ44355459-0F49504B-778F-4A48-A063-9233D0983B7FQ47204696-08D5466C-4901-4DCD-BEA6-CE50C8CE0191Q51625767-F8FB9BE4-A095-4A61-9ACE-3C17EA4247FFQ55317261-DB908A57-0A98-4673-8DE9-6771FB105229Q57815879-37E3F64F-C45C-44B0-99D8-B744A2276E85
P2860
HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HIV and antiretroviral therapy ...... risk in HIV-infected patients.
@en
HIV and antiretroviral therapy ...... risk in HIV-infected patients.
@nl
type
label
HIV and antiretroviral therapy ...... risk in HIV-infected patients.
@en
HIV and antiretroviral therapy ...... risk in HIV-infected patients.
@nl
prefLabel
HIV and antiretroviral therapy ...... risk in HIV-infected patients.
@en
HIV and antiretroviral therapy ...... risk in HIV-infected patients.
@nl
P921
P1476
HIV and antiretroviral therapy ...... risk in HIV-infected patients.
@en
P2093
Donald P Kotler
P304
P356
10.1097/QAI.0B013E318186519C
P407
P478
49 Suppl 2
P577
2008-09-01T00:00:00Z